Page last updated: 2024-10-28

hydroxyurea and Malaria

hydroxyurea has been researched along with Malaria in 14 studies

Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.

Research Excerpts

ExcerptRelevanceReference
"Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown."9.24Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. ( Hodges, JS; Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Ndugwa, CM; Opoka, RO; Ware, RE, 2017)
"Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention."7.11Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022)
"Splenomegaly is an unexplained risk factor for malaria infections among children with SCA in Africa."5.91Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. ( Aygun, B; Howard, TA; Lane, A; Latham, TS; McElhinney, K; Olupot-Olupot, P; Santos, B; Smart, LR; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2023)
"Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown."5.24Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. ( Hodges, JS; Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Ndugwa, CM; Opoka, RO; Ware, RE, 2017)
"Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention."3.11Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022)
"Hydroxyurea has proven safety, feasibility, and efficacy in children with sickle cell anemia in sub-Saharan Africa, with studies showing a reduced incidence of vaso-occlusive events and reduced mortality."2.94Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. ( Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Nabaggala, C; Ndugwa, CM; Opoka, RO; Ware, RE, 2020)
"Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa."2.90Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. ( Aygun, B; Lane, A; Latham, TS; McGann, PT; Olupot-Olupot, P; Santos, B; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2019)
" The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa."2.87Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. ( Aygun, B; Howard, TA; Kitenge, R; Lane, A; Latham, T; Luís Reis da Fonseca, J; McElhinney, K; McGann, PT; Mochamah, G; Olupot-Olupot, P; Santos, B; Stuber, S; Tomlinson, GA; Tshilolo, L; Wabwire, H; Ware, RE; Williams, TN, 2018)
"Because malaria is thought to be a significant cause of morbidity and mortality in patients with SCD, malaria chemoprophylaxis is often recommended for these patients."2.49Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. ( Aneni, EC; Gill, CJ; Hamer, DH, 2013)
"Splenomegaly is an unexplained risk factor for malaria infections among children with SCA in Africa."1.91Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. ( Aygun, B; Howard, TA; Lane, A; Latham, TS; McElhinney, K; Olupot-Olupot, P; Santos, B; Smart, LR; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2023)
" These data endorse broad, safe, and long-term use of HU for SCA in malaria-endemic countries and provide a novel biological model for the treatment of a genetic disorder with simultaneous, adjunct therapy of a life-threatening infection needed in a global health setting."1.91Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. ( Haldar, K; Mohandas, N; Safeukui, I; Ware, RE, 2023)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's0 (0.00)29.6817
2010's6 (42.86)24.3611
2020's7 (50.00)2.80

Authors

AuthorsStudies
Taylor, SM1
Korwa, S1
Wu, A1
Green, CL1
Freedman, B1
Clapp, S1
Kirui, JK1
O'Meara, WP1
Njuguna, FM1
Olupot-Olupot, P3
Tomlinson, G2
Williams, TN3
Tshilolo, L3
Santos, B3
Smart, LR1
McElhinney, K2
Howard, TA2
Aygun, B3
Stuber, SE2
Lane, A5
Latham, TS4
Ware, RE6
Odame, I2
Safeukui, I1
Mohandas, N1
Haldar, K1
Archer, NM1
John, CC2
Opoka, RO2
Hume, HA2
Nabaggala, C1
Kasirye, P2
Ndugwa, CM2
Cavanaugh, R1
Hodges, JS1
McGann, PT2
Tomlinson, GA1
Luís Reis da Fonseca, J1
Kitenge, R1
Mochamah, G1
Wabwire, H1
Stuber, S1
Latham, T1
Chung, DW1
Ponts, N1
Prudhomme, J1
Rodrigues, EM1
Le Roch, KG1
Aneni, EC1
Hamer, DH1
Gill, CJ1
Hardeman, MR1
Ince, C1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)[NCT03178643]Phase 4246 participants (Actual)Interventional2018-01-23Completed
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study[NCT03128515]Phase 3187 participants (Actual)Interventional2017-07-26Completed
Novel Use Of Hydroxyurea in an African Region With Malaria[NCT01976416]Phase 3208 participants (Actual)Interventional2014-09-30Completed
REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731]Phase 1/Phase 2635 participants (Actual)Interventional2014-06-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Malaria Episodes

Malaria is defined as the presence of P. falciparum or P. malariae on the peripheral smear of any child brought in for medical evaluation of fever. P. vivax, P. ovale and P. knowlesi are not known to be present in this region, but if a child is seen with suspected infection with any of these malaria parasites, this will also be recorded as a case of malaria. Incidence will be reported in the number of cases per 100 patient years. (NCT01976416)
Timeframe: 12 months

Interventionmalaria episodes (Number)
Hydroxyurea5
Placebo7

Percentage of Participants With Dose Limiting Toxic Events

An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months

Interventionpercentage of participants (Number)
Hydroxyurea5.1

Reviews

1 review available for hydroxyurea and Malaria

ArticleYear
Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.
    Tropical medicine & international health : TM & IH, 2013, Volume: 18, Issue:3

    Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antimalarials; Antisickling Agents; Comorbidity; Dr

2013

Trials

5 trials available for hydroxyurea and Malaria

ArticleYear
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
    PLoS medicine, 2022, Volume: 19, Issue:10

    Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Presch

2022
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    The New England journal of medicine, 2020, 06-25, Volume: 382, Issue:26

    Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Dose-Response Relationship, Drug; Double

2020
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Blood, 2017, 12-14, Volume: 130, Issue:24

    Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Child, Preschool; Double-Blind Method; E

2017
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
    American journal of hematology, 2018, Volume: 93, Issue:4

    Topics: Africa South of the Sahara; alpha-Thalassemia; Anemia, Sickle Cell; Blood Transfusion; Child; Child,

2018
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    The New England journal of medicine, 2019, 01-10, Volume: 380, Issue:2

    Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose-

2019

Other Studies

8 other studies available for hydroxyurea and Malaria

ArticleYear
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
    Blood, 2023, 03-23, Volume: 141, Issue:12

    Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Incidence; Malaria; Spl

2023
HU for SCA in Africa: associated malaria benefit.
    Blood, 2023, 03-23, Volume: 141, Issue:12

    Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Incidence; Malaria

2023
Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia.
    Blood advances, 2023, 10-10, Volume: 7, Issue:19

    Topics: Anemia, Sickle Cell; Blood Transfusion; Erythrocytes; Humans; Hydroxyurea; Malaria; Malaria, Falcipa

2023
Further evidence supporting the global use of hydroxyurea.
    Blood advances, 2023, 10-10, Volume: 7, Issue:19

    Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Malaria

2023
Lucio Luzzatto: tackling blood disorders on multiple continents.
    The Lancet. Haematology, 2021, Volume: 8, Issue:4

    Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Bone Marrow Examination; Glucosephos

2021
Hydroxyurea for SCA in Africa: no malaria harm.
    Blood, 2017, 12-14, Volume: 130, Issue:24

    Topics: Africa; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Malaria

2017
Characterization of the ubiquitylating components of the human malaria parasite's protein degradation pathway.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Amino Acid Sequence; Endoplasmic Reticulum; Endoplasmic Reticulum-Associated Degradation; Host-Paras

2012
Clinical potential of in vitro measured red cell deformability, a myth?
    Clinical hemorheology and microcirculation, 1999, Volume: 21, Issue:3-4

    Topics: Adult; Age Factors; Anemia, Sickle Cell; Cell Count; Child, Preschool; Cyclosporine; Elliptocytosis,

1999